Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

This trial is designed to examine the effect of exenatide once weekly compared to exenatide
twice daily on glucose control and safety in subjects for at least 30 weeks. The study is
also designed to examine glucose control during the transition from exenatide twice daily
for 30 weeks to exenatide once weekly. Long-term safety and efficacy will be monitored
during the open-ended assessment periods. This study will be conducted in approximately 300
subjects with type 2 diabetes treated with diet modification and exercise alone or in
combination with a stable regimen of metformin, SU, thiazolidinedione (TZD), a combination
of metformin and SU, a combination of metformin and TZD, or a combination of SU and TZD.

Inclusion Criteria:

- Has type 2 diabetes mellitus treated with diet modification and exercise alone or in
combination with a stable regimen of a combination of metformin, sulphonylureas, and
thiazolidinediones for a minimum of 2 months at screening.

- Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening.

- Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.

- (For sub-study) Currently participating in open ended assessment period of main study
2993 LAR105

Exclusion Criteria:

- Has been previously exposed to exenatide (Byetta®), exenatide LAR, or any
glucagon-like peptide-1 (GLP-1) analog.

- Received any investigational drug or has participated in any type of clinical trial
within 30 days prior to screening.

- Has been treated, is currently treated, or is expected to require or undergo
treatment with any of the following excluded medications:

- Alpha glucosidase inhibitor or meglitinide within 30 days of screening;

- Insulin within 2 weeks prior to screening or insulin for longer than 1 week
within 3 months of screening;

- Regular use (> 14 days) of drugs that directly affect gastrointestinal motility;

- Regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or
intramuscular route; or potent, inhaled, or intrapulmonary steroids known to
have a high rate of systemic absorption;

- Regular use (> 14 days) of medications with addictive potential such as opiates
and opioids;

- Prescription or over-the-counter weight loss medications within 6 months of
screening.

- (For sub-study) Subjects will be terminated from study who do not participate in the
dual chamber pen substudy